imiquimod has been researched along with imatinib mesylate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Biedrzycki, B; Chia, C; Garrett-Mayer, E; Gocke, C; Harding, TC; Hege, K; Jones, R; Kasamon, YL; Kowalski, J; Levitsky, HI; Miller, CB; Murphy, K; Qin, L; Smith, BD; Tsai, HL; Tu, GH | 1 |
| Grimes, PE; Nashawati, R | 1 |
| Egusa, C; Harada, K; Hayakawa, K; Maeda, T; Okubo, Y | 1 |
1 review(s) available for imiquimod and imatinib mesylate
| Article | Year |
|---|---|
Depigmentation Therapies for Vitiligo.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anisoles; Body Surface Area; Cryotherapy; Cyclopropanes; Humans; Hydroquinones; Imatinib Mesylate; Imiquimod; Low-Level Light Therapy; Patient Selection; Phenol; Protein Kinase Inhibitors; Severity of Illness Index; Skin Lightening Preparations; Vitiligo | 2017 |
1 trial(s) available for imiquimod and imatinib mesylate
| Article | Year |
|---|---|
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Topics: Adult; Aged; Aminoquinolines; Benzamides; Cancer Vaccines; Female; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Imiquimod; Immunotherapy; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Piperazines; Pyrimidines; Tumor Burden | 2010 |
1 other study(ies) available for imiquimod and imatinib mesylate
| Article | Year |
|---|---|
Topical application of imatinib mesylate ameliorated psoriasis-like skin lesions in imiquimod-induced murine model via angiogenesis inhibition.
Topics: Animals; Disease Models, Animal; Humans; Imatinib Mesylate; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases; Vascular Endothelial Growth Factor A | 2023 |